Clinical Response of Live-Attenuated,
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cisplatin
/ administration & dosage
Combined Modality Therapy
Female
GPI-Linked Proteins
/ immunology
Humans
Listeria monocytogenes
/ immunology
Lung Neoplasms
/ immunology
Male
Mesothelin
Mesothelioma
/ immunology
Mesothelioma, Malignant
Middle Aged
Pemetrexed
/ administration & dosage
Pleural Neoplasms
/ immunology
Survival Rate
Tumor Microenvironment
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
received:
08
01
2019
revised:
09
05
2019
accepted:
26
06
2019
pubmed:
3
7
2019
medline:
26
9
2020
entrez:
3
7
2019
Statut:
ppublish
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with poor prognosis. CRS-207 is a live-attenuated Patients with unresectable MPM, ECOG 0 or 1, and adequate organ and pulmonary function were enrolled in this multicenter, open-label phase Ib study. They received two priming infusions of 1 × 10 Of 35 evaluable patients, 89% (31/35) had disease control with one complete response (3%), 19 partial responses (54%), and 10 stable disease (29%). The estimated median duration of response was 5.0 months (95% CI, 3.9-11.5). The median PFS and OS were 7.5 (95% CI, 7.0-9.9) and 14.7 (95% CI, 11.2-21.9) months, respectively. Tumor size reduction was observed post-CRS-207 infusion prior to chemotherapy in 11 of 35 (31%) patients. No unexpected treatment-related serious adverse events or deaths were observed. IHC analysis of pre- and post-CRS-207 treatment tumor biopsies revealed possible reinvigoration and proliferation of T cells, increased infiltration of dendritic and natural killer cells, increased CD8:T Combination of CRS-207 and chemotherapy induced significant changes in the local tumor microenvironment and objective tumor responses in a majority of treated patients.
Identifiants
pubmed: 31263030
pii: 1078-0432.CCR-19-0070
doi: 10.1158/1078-0432.CCR-19-0070
pmc: PMC8132300
mid: NIHMS1696944
doi:
Substances chimiques
GPI-Linked Proteins
0
Pemetrexed
04Q9AIZ7NO
Mesothelin
J27WDC343N
Cisplatin
Q20Q21Q62J
Banques de données
ClinicalTrials.gov
['NCT01675765']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
5787-5798Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000128
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA163123
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 BC010816
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC010816
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011793
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Br J Cancer. 2009 Dec 1;101(11):1869-75
pubmed: 19935800
Cancer Res. 2003 Aug 1;63(15):4490-6
pubmed: 12907622
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Urol. 2005 Aug;174(2):539-46
pubmed: 16006888
Cancer. 2014 Nov 1;120(21):3311-9
pubmed: 24989332
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20
pubmed: 16702385
Ann Cardiothorac Surg. 2012 Nov;1(4):491-6
pubmed: 23977542
Clin Cancer Res. 2005 Jun 15;11(12):4430-6
pubmed: 15958627
Nat Rev Immunol. 2004 Oct;4(10):812-23
pubmed: 15459672
Saf Health Work. 2012 Mar;3(1):17-21
pubmed: 22953226
J Clin Oncol. 2015 Apr 20;33(12):1325-33
pubmed: 25584002
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87
pubmed: 16467102
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7
pubmed: 15365184
Mol Ther. 2010 Nov;18(11):1947-59
pubmed: 20683443
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Clin Cancer Res. 2011 Mar 1;17(5):1181-9
pubmed: 21177406
N Engl J Med. 2005 Oct 13;353(15):1591-603
pubmed: 16221782
J Clin Oncol. 2010 Jul 10;28(20):3316-22
pubmed: 20498407
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1520-6
pubmed: 18559570
Am J Clin Pathol. 2005 Dec;124(6):838-45
pubmed: 16416732
J Thorac Cardiovasc Surg. 2008 Apr;135(4):823-9
pubmed: 18374762
Cancer Res. 2008 Jul 15;68(14):5955-64
pubmed: 18632651
Am J Respir Crit Care Med. 2010 Jun 15;181(12):1383-90
pubmed: 20167848
J Cell Biol. 2002 Aug 5;158(3):409-14
pubmed: 12163465
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
J Virol. 1996 May;70(5):2902-10
pubmed: 8627765
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7
pubmed: 16082249
Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3987-91
pubmed: 7732018
Chest. 1993 Apr;103(4 Suppl):377S-381S
pubmed: 8462329
Clin Cancer Res. 2001 Dec;7(12):3862-8
pubmed: 11751476
J Clin Oncol. 2012 May 1;30(13):1541-9
pubmed: 22412141
Occup Environ Med. 2011 Jul;68(7):547-9
pubmed: 21422006
Clin Cancer Res. 2012 Feb 1;18(3):858-68
pubmed: 22147941
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Am J Surg Pathol. 2003 Nov;27(11):1418-28
pubmed: 14576474
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Vaccine. 2007 Sep 27;25 Suppl 2:B89-96
pubmed: 17573164
J Thorac Oncol. 2011 Nov;6(11):1930-7
pubmed: 21841505
Cancer Res. 1992 Jan 1;52(1):181-6
pubmed: 1727378
Clin Cancer Res. 2004 Aug 15;10(16):5316-26
pubmed: 15328167
Int J Cancer. 1992 Feb 1;50(3):373-81
pubmed: 1735605
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Ann Oncol. 2004 Feb;15(2):257-60
pubmed: 14760119
Am J Ind Med. 2005 Dec;48(6):419-31
pubmed: 16299703